Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience.

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research.

Study demonstrates proof-of-concept and strong safety profile of Aurase Wound Gel in patients suffering from chronic wounds.

Semeta™ offers high sensitivity and superior precision for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery.

Cresset, announces a collaboration with Enamine to develop innovative new solutions for the early drug discovery process.

N4 Pharma PLC (AIM: N4P), recently acquired a controlling interest in Nanogenics Limited.

BioCina Pty Ltd., and NovaCina Pty Ltd., announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers.

TriLink’s CleanCap^® capping technology is patented globally & TriLink is the sole authorized manufacturer of CleanCap^® capping analogs

AMSBIO describe how life science research groups are using their BioPORTER®, Detachin™, and SoluLyse™ reagents to make groundbreaking advances in Parkinson’s research, hypersomnia studies and eco-friendly microbial ester production.

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking. The software promotes collaboration within and across teams for more cohesive workflows